Comparing these options honestly starts with an uncomfortable finding. No peptide sold for energy has established human evidence that it raises energy in healthy adults, and two of the most heavily promoted candidates have no published human administration data at all. A useful checklist therefore ranks evidence first, medical workup second, and vendor features last.
The first item on the checklist is not a product
Fatigue is one of the most common reasons adults book a primary care appointment. The standard evaluation sorts it into physiologic, secondary, or chronic categories using history and physical examination, and secondary fatigue improves when the cause underneath it is treated. Anemia, thyroid disease, sleep apnea, depression, medication effects, and chronic short sleep account for a large share of what people describe as low energy, and each has treatment that outperforms anything in this category.
The diagnostic gap here is real enough that a multicenter primary care trial tested a structured aid built specifically for patients whose fatigue had no obvious cause. A checklist that skips this step is comparing products for a problem it has not yet defined.
One nuance cuts in both directions. In a study nested inside the randomized TRUST trial, thyroid hormone therapy in older adults with mild subclinical hypothyroidism produced no change in physical or mental fatigability across a year. An abnormal lab value does not automatically explain a symptom, and correcting it does not automatically fix one.
Rank each compound by human evidence, not by mechanism
Mechanism stories are easy to write and hard to falsify. Every compound below has a plausible one. What separates them is whether anyone has tested it in people.
| Compound | Common energy claim | What human evidence actually exists |
|---|---|---|
| MOTS-c | Mitochondrial peptide that restores cellular energy output | No published trials of administration in people. FDA states it has identified no human exposure data for any route. Observational work has measured naturally circulating levels and found they track muscle strength rather than aerobic capacity |
| SS-31 (elamipretide) | Repairs mitochondria and lifts fatigue | The most studied of the group. A phase 3 trial in 218 people with genetically confirmed primary mitochondrial myopathy missed both primary endpoints, walking distance and total fatigue score. It received accelerated FDA approval in September 2025 for Barth syndrome, a rare inherited disorder, with a confirmatory trial required |
| Nicotinamide riboside | Raises NAD+ and restores youthful energy | Trials consistently show blood NAD+ rises. Function is a separate question: a randomized placebo-controlled trial in men with obesity found no improvement in insulin sensitivity and no effect on resting energy expenditure |
| Nicotinamide mononucleotide | The same NAD+ premise in a newer molecule | One 12-week randomized trial in 108 older Japanese adults reported better sit-to-stand performance and less drowsiness in one dosing arm. Single study, narrow population, not replicated at scale |
| Intravenous NAD+ | The fastest route to cellular energy | A systematic review of 113 intervention studies found no eligible outcomes trials of intravenous or intramuscular NAD+ for wellness indications. A retrospective review of a commercial clinic recorded moderate to severe gastrointestinal symptoms, raised heart rate, and chest pressure during infusions |
| 5-Amino-1MQ | Blocks NNMT, raises NAD+, converts fat to energy | None. The published record on this class of inhibitor is cell culture and rodent work |
| Sermorelin | Growth hormone release restores vitality | Human data exists, but it concerns diagnosis and treatment of growth hormone deficiency, not energy in people with normal pituitary function |
Treat regulatory status as its own column
FDA has placed several of these peptides on a published list of bulk drug substances that may present significant safety risks when used in compounding, citing immunogenicity risk by certain routes, peptide-related impurities, and difficulty characterizing the active ingredient. MOTS-c, BPC-157, CJC-1295, ipamorelin acetate, and AOD-9604 all appear there.
Compounded preparations are not FDA-approved. They are not reviewed for safety, effectiveness, or quality before a patient receives them. That is a fact about the product category, and it belongs on the checklist next to price rather than in fine print. Material sold as a research chemical not for human consumption sits outside the pharmacy system entirely.
Only then compare the people supplying it
Once evidence tier and legal status are written down, provider comparison gets narrow and answerable. Ask whether a licensed clinician reviews the case before anything is dispensed, which pharmacy fills the order and under which section of the compounding law, whether labs are ordered and interpreted, and what the total annual cost is once consult fees and shipping are counted.
The field is not uniform. Direct-to-consumer telehealth brands such as Hims and Hers and Ro, performance and longevity clinics such as Marek Health, supplement makers such as Tru Niagen, and physician-supervised compounding services including FormBlends operate under different rules and answer to different regulators. Comparing a supplement to a compounded injectable on price alone produces a meaningless number, because the two are not the same kind of product and do not carry the same oversight.
Signals that should end a comparison early
A vendor that cites rodent studies without saying they are rodent studies has told you how it handles evidence. So has one that describes a compound as clinically proven when the clinical record is a correlation in twenty volunteers. Published analyses of falsified polypeptide products bought online have found wide variation in active ingredient content, and analytical chemists once found undeclared mannitol making up a substantial share of custom synthetic peptides ordered from commercial suppliers.
Anything promising a defined percentage gain in energy is describing an outcome nobody has measured. There is no validated endpoint for energy in healthy adults, which is part of why this field has so little to show.
The same test applies to the sites doing the selling. A reader comparing named options, from Henry Meds and LifeMD to providers such as HealthRX that publish their own peptide therapy pages, should weight the ones that state plainly that nothing in this category has human evidence for raising energy and that a compounded preparation is not FDA-approved. A page that instead leads with a fixed percentage gain has already shown how it treats the record.
Frequently asked questions
Is any peptide FDA-approved for energy or fatigue?
No. Elamipretide holds an accelerated approval for Barth syndrome, a rare inherited mitochondrial disorder, and tesamorelin and sermorelin have narrow approved uses of their own. Nothing in this category is approved for energy, fatigue, or athletic performance in otherwise healthy people.
Does raising NAD+ raise energy?
Oral precursors reliably raise measured NAD+ in blood, which is target engagement rather than benefit. A systematic review found that effects on functional and metabolic outcomes in humans were mixed and frequently null. Biochemical activity and a felt result are different claims.
What if standard bloodwork comes back normal?
A normal panel narrows the list without closing it. Sleep duration and quality, screening for sleep apnea, mood, alcohol, and a medication review sit outside a basic panel, and post-exertional malaise points somewhere different again. Normal results are information, not a dead end.
Are research-chemical peptides the same product as compounded ones?
No. Compounded preparations come from a licensed pharmacy against a prescription, with state board oversight and, for outsourcing facilities, federal registration. Research chemicals carry none of that, and the analytical literature on internet-sourced peptides documents contamination and content that does not match the label.
How should evidence and price be weighted against each other?
Evidence first. A cheaper compound with no human data is not a better deal than an expensive one, because both are buying an unknown. Price becomes a useful tiebreaker only among options that clear the same evidence bar.
